-

Did You Lose Money in Your Blue Owl Capital Inc. Investment? Contact Robbins LLP for Information About Your Rights Against OWL.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of Blue Owl Capital Inc. (NYSE: OWL) investors.

Robbins LLP is Investigating Allegations that Blue Owl Capital Inc. (OWL) Misled Investors Regarding its Business Prospects

Share

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is the class period? February 6, 2025 – November 16, 2025

What are the Allegations? Robbins LLP is Investigating Allegations that Blue Owl Capital Inc. (OWL) Misled Investors Regarding its Business Prospects

According to the complaint, during the class period, defendants failed to disclose that: (1) Blue Owl was experiencing meaningful pressure on its asset base from BDC [business development company] redemptions; (2) as a result, the Company was facing undisclosed liquidity issues; (3) as a result, the Company would be likely to limit or halt redemptions of certain BDCs; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading. When the truth was revealed, Blue Owl's stock price fell, harming investors.

What can you do now? You may be eligible to participate in the class action against Blue Owl Capital Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by February 2, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Blue Owl Capital Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:OWL

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Did You Lose Money in Stride, Inc.? Contact Robbins LLP for Information About Your Rights Against LRN.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: The company: Stride, Inc. (NYSE: LRN) is a technology company that provides an education platform to deliver online learning to students throughout the U.S. What is the class period? October 22, 2024 - October 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Stride during the class period because the Company allegedly misled investors regarding i...

Did You Lose Money in Perrigo Company? PRGO Stockholders Should Contact Robbins LLP for Information About Their Rights Against PRGO.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally. What is the class period? February 27, 2024 - November 4, 2025 What is the Case About? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who acquired Perrigo securities during the class period because the Company allegedly misled investors regarding the value of its infant formula...

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. What is the class period? November 4, 2024 - October 3, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors...
Back to Newsroom